{
  "report_rows": [],
  "guide_rows": [],
  "day1_residual_pct": 405024.6,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.0,
  "day5_path": "FADE",
  "day5_rationale": " Print is a placeholder \u2014 thin trough revenue (~$80M) and a wide GAAP loss dominated by the Q3 Arbutus payment. Any day-1 weakness on a soft top-line miss/fragile post-rally positioning is likely to fade because the genuinely binary catalyst \u2014 the Aug 5 mRNA-1010 flu PDUFA (well de-risked by the unanimous AdCom vote and positive briefing docs) \u2014 falls inside the 5-day window; an approval is a fifth product and sentiment win in a hostile policy backdrop, though heavy prior de-risking caps upside and keeps net drift modest.",
  "day5_confidence": "LOW"
}